Article | Published:

Intermittent hypoxia induces a metastatic phenotype in breast cancer

Oncogenevolume 37pages42144225 (2018) | Download Citation

Abstract

Hypoxia arises frequently in solid tumors and is a poor prognostic factor as it promotes tumor cell proliferation, invasion, angiogenesis, therapy resistance, and metastasis. Notably, there are two described forms of hypoxia present in a growing tumor: chronic hypoxia, caused by abnormal tumor vasculature, and intermittent hypoxia, caused by transient perfusion facilitated by tumor-supplying blood vessels. Here, we demonstrate that intermittent hypoxia, but not chronic hypoxia, endows breast cancer cells with greater metastatic potential. Using an immunocompetent and syngeneic murine model of breast cancer, we show that intermittent hypoxia enhances metastatic seeding and outgrowth in lungs in vivo. Furthermore, exposing mammary tumor cells to intermittent hypoxia promoted clonal diversity, upregulated metastasis-associated gene expression, induced a pro-tumorigenic secretory profile, increased stem-like cell marker expression, and gave rise to tumor-initiating cells at a relatively higher frequency. This work demonstrates that intermittent hypoxia, but not chronic hypoxia, induces a number of genetic, molecular, biochemical, and cellular changes that facilitate tumor cell survival, colonization, and the creation of a permissive microenvironment and thus enhances metastatic growth.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16:5928–35.

  2. 2.

    Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207–14.

  3. 3.

    Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.

  4. 4.

    Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2009;29:625–34.

  5. 5.

    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.

  6. 6.

    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32.

  7. 7.

    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.

  8. 8.

    Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J. 2008;275:2991–3002.

  9. 9.

    Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors. Strahlenther Onkol. 2012;188:616–27.

  10. 10.

    Kamat CD, Green DE, Warnke L, Thorpe JE, Ceriello A, Ihnat MA. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007;249:209–19.

  11. 11.

    Alqawi O, Wang HP, Espiritu M, Singh G. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res. 2007;41:788–97.

  12. 12.

    Hussein D, Estlin EJ, Dive C, Makin GWJ. Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther. 2006;5:2241–50.

  13. 13.

    Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008;68:605–14.

  14. 14.

    Zölzer F, Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys. 2002;54:910–20.

  15. 15.

    Bhaskara VK, Mohanam I, Rao JS, Mohanam S. Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One. 2012;7:e30905.

  16. 16.

    Daneau G, Boidot R, Martinive P, Feron O. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases. Clin Cancer Res. 2010;16:410–9.

  17. 17.

    Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS, et al. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol. 2011;38:733.

  18. 18.

    Hsieh C-H, Chang H-T, Shen W-C, Shyu W-C, Liu R-S. Imaging the impact of Nox4 in cycling hypoxia-mediated U87 glioblastoma invasion and infiltration. Mol Imaging Biol. 2012;14:489–99.

  19. 19.

    Hsieh C-H, Lee C-H, Liang J-A, Yu C-Y, Shyu W-C. Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncol Rep. 2010;24:1629–36.

  20. 20.

    Hsieh C-H, Shyu W-C, Chiang C-Y, Kuo J-W, Shen W-C, Liu R-S. NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One. 2011;6:e23945.

  21. 21.

    Liu Y, Song X, Wang X, Wei L, Liu X, Yuan S, et al. Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells. J Cell Biochem. 2010;111:554–63.

  22. 22.

    Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Grégoire V, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 2006;66:11736–44.

  23. 23.

    Miao Z-F, Zhao T-T, Wang Z-N, Xu Y-Y, Mao X-Y, Wu J-H, et al. Influence of different hypoxia models on metastatic potential of SGC-7901 gastric cancer cells. Tumor Biol. 2014;35:6801–8.

  24. 24.

    Mujcic H, Nagelkerke A, Rouschop KMA, Chung S, Chaudary N, Span PN, et al. Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3. Am Assoc Cancer Res. 2013;19:6126–37.

  25. 25.

    Rofstad EK, Gaustad J-V, Egeland TAM, Mathiesen B, Galappathi K. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer. 2010;127:1535–46.

  26. 26.

    Rouschop KMA, Ramaekers CHMA, Schaaf MBE, Keulers TGH, Savelkouls KGM, Lambin P. et al. Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol. 2009;92:411–16.

  27. 27.

    Zhu H, Wang D, Zhang L, Xie X, Wu Y, Liu Y, et al. Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133 + pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep. 2014;32:935–42.

  28. 28.

    Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 2004;64:2054–61.

  29. 29.

    Cairns RA, Kalliomaki T, Hill RP. Acute (Cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 2001;61:8903–8.

  30. 30.

    Cooper C, Liu G-Y, Niu Y-L, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clin Cancer Res. 2004;10:8720–7.

  31. 31.

    Kalliomäki TM, McCallum G, Wells PG, Hill RP. Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia. Cancer Lett. 2009;282:98–108.

  32. 32.

    Louie E, Nik S, Chen J-s, Schmidt M, Song B, Pacson C, et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 2010;12:R94.

  33. 33.

    Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24.

  34. 34.

    Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399–405.

  35. 35.

    Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, Andrews DM, et al. Primary tumor hypoxia recruits CD11b + /Ly6Cmed/Ly6G + immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012;72:3906–11.

  36. 36.

    Ma J, Lanza D, Guest I, Uk-Lim C, Glinskii A, Glinsky G, et al. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumor Biol. 2012;33:1983–96.

  37. 37.

    Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–78.

  38. 38.

    Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell. 2006;10:413–23.

  39. 39.

    Perez-Mancera PA, Young ARJ, Narita M. Inside and out: the activities of senescence in cancer. Nat Rev Cancer. 2014;4:547–58.

  40. 40.

    Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–51.

  41. 41.

    Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019–31.

  42. 42.

    Aguirre Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834.

  43. 43.

    Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611–22.

  44. 44.

    Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961–7.

  45. 45.

    He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67–93.

  46. 46.

    Fang Y, Tan J, Zhang Q. Signaling pathways and mechanisms of hypoxia-induced autophagy in the animal cells. Cell Biol Int. 2015;39:891–8.

  47. 47.

    Mazure NM, Pouysségur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol. 2010;22:177–80.

  48. 48.

    Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8:1369–75.

  49. 49.

    Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10:1349–55.

  50. 50.

    Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.

  51. 51.

    Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN[gamma] and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11.

  52. 52.

    Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67:10019–26.

  53. 53.

    Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337–43.

  54. 54.

    Gutsche K, Randi EB, Blank V, Fink D, Wenger RH, Leo C, Scholz CC. Intermittent hypoxia confers pro-metastatic gene expression selectively through NF-κB in inflammatory breast cancer cells. Free Radic Biol Med. 2016;101:129–42.

  55. 55.

    Boidot R, Branders S, Helleputte T, Rubio LI, Dupont P, Feron O. A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling. Oncotarget. 2014;5:6947–63.

  56. 56.

    Wong CSF, Sceneay J, House CM, Halse HM, Liu MCP, George J, et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. Cancer Res. 2012;72:1694–704.

  57. 57.

    Chen A, Wong CSF, Liu MCP, House CM, Sceneay J, Bowtell DD, et al. The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer. Oncotarget. 2014;6:862–73.

  58. 58.

    Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Meth. 2012;9:671–5.

  59. 59.

    Möller A, House CM, Wong CSF, Scanlon DB, Liu MCP, Ronai Z, et al. Inhibition of Siah ubiquitin ligase function. Oncogene. 2009;28:289–96.

  60. 60.

    Sceneay J, Liu MCP, Chen A, Wong CSF, Bowtell DDL, Möller A. The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo. PLoS One. 2013;8:e66388.

Download references

Acknowledgements

The authors thank Carmen Yong for help with flow cytometry and IV injections, and the groups of POH and AM for proof-reading the manuscript. This work was supported by funding from a project grant from the National Health and Medical Research Council of Australia (APP1068510 to AM). POH was supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia (APP1079133). AM was supported by Cancer Council Queensland (APP1045620), and National Breast Cancer Foundation (Australia) fellowship and grant (ECF-11-09, NC-13-26). AC was supported by an APA scholarship.

Author information

Author notes

    • Jaclyn Sceneay

    Present address: Brigham & Women’s Hospital, Boston, MA, 02115, USA

Affiliations

  1. Cell Cycle and Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, VIC, 3002, Australia

    • Anna Chen
    • , Nathan Gödde
    • , Tanja Kinwel
    •  & Patrick O Humbert
  2. Department of Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia

    • Anna Chen
    • , Tanja Kinwel
    •  & Patrick O Humbert
  3. Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD, 4006, Australia

    • Anna Chen
    • , Jaclyn Sceneay
    • , Sunyoung Ham
    •  & Andreas Möller
  4. Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia

    • Nathan Gödde
    • , Tanja Kinwel
    •  & Patrick O Humbert
  5. Sir Peter MaCallum Department of Oncology, The University of Melbourne, Parkville, VIC, 3010, Australia

    • Nathan Gödde
    •  & Patrick O Humbert
  6. Pathology and Pathogenesis Group, Diagnostics Surveillance & Response, Australian Animal Health Laboratory, CSIRO, Geelong, VIC, 3220, Australia

    • Nathan Gödde
  7. Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Brisbane, QLD, 4000, Australia

    • Erik W Thompson
  8. Department of Surgery, The University of Melbourne, St. Vincent’s Hospital, East Melbourne, 3002, Australia

    • Erik W Thompson
  9. Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, 3010, Australia

    • Patrick O Humbert

Authors

  1. Search for Anna Chen in:

  2. Search for Jaclyn Sceneay in:

  3. Search for Nathan Gödde in:

  4. Search for Tanja Kinwel in:

  5. Search for Sunyoung Ham in:

  6. Search for Erik W Thompson in:

  7. Search for Patrick O Humbert in:

  8. Search for Andreas Möller in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding authors

Correspondence to Patrick O Humbert or Andreas Möller.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41388-018-0259-3

Further reading